HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

The company maintains its target to address 12,000 CIDP patients, focusing on those with unmet needs and leveraging the momentum achieved through its MG playbook. Plans to advance 10 Phase III and ...

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the opening ...

Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

Argenx’s ad focuses on two people with CIDP, played by actors but inspired by the patient community. The ad opens with a woman heading toward a car with the support of a walking stick.

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Roughly 85% of those CIDP patients have switched over to Vyvgart from intravenous immunoglobulin treatment, in line with argenx’s expectations prior to the launch, Massey pointed out.

We expanded our reach to over 10,000 patients globally across 3 approved indications and delivered significant impacts to the CIDP community early into launch. We also achieved several key ...

Argenx (NASDAQ: ARGX) has been upgraded to an "outperform" rating from "underperform" by Bernstein, with the price target revised sharply upwards to €755 from 1 ...

A patient from Reading who needed lifesaving treatment developed from blood plasma has thanked donors. Over the past three ...